Don’t Jump to Caplyta or Secuado for Schizophrenia

April 2020

Caplyta (kah-PLY-tah, lumateperone) and Secuado (seh-KWAH-doh, asenapine) will be two new atypical antipsychotics.

There are now over a dozen of these second-generation options...with varying activity at receptors (dopamine, serotonin, etc).

But efficacy seems similar.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote